Content in review
Results / Europe & the CIS / Turkmenistan
Let me know when the updated version of the UNDP Health Systems website is online:
Turkmenistan
Key results - TB
Case detection rate for TB (2017)
Source: World Health Organization
TB treatment coverage (2017)
Source: World Health Organization
Treatment success rate for all new cases of TB (2016)
Source: World Health Organization
TB incidence
Source: World Health Organization
TB related mortality
Source: World Health Organization
Key results - Multidrug-Resistant Tuberculosis (MDR-TB)
Multidrug-resistant TB (MDR-TB) is TB that does not respond to at least isoniazid and rifampicin, the 2 most powerful anti-TB drugs. The 2 reasons why multidrug resistance continues to emerge, and spread are mismanagement of TB treatment and person-to-person transmission. In some cases, even more severe drug-resistant TB may develop. Extensively drug-resistant TB, XDR-TB, is a form of multidrug-resistant TB with additional resistance to more anti-TB drugs that therefore responds to even fewer available medicines. It has been reported in 117 countries worldwide.
1,957 MDR-TB cases were enrolled on treatment in Turkmenistan between 2013 and 2016. Treatment of extremely drug-resistant TB (XDR-TB) with “novel“ TB drugs is available since mid-2017. Ninety four percent of national tuberculosis programme needs are currently covered by the Government of Turkmenistan. Being an upper middle-income country, Turkmenistan received the Global Fund’s transitional grant for 2018-2021. This grant is the last to be funded by the Global Fund and supports the National TB Programme’s Sustainability and Transition Plan activities.
340 estimated cases of MDR or RR-TB (2017)
Source: World Health Organization
Treatment success rate for MDR-TB (2017)
Source: World Health Organization
1,957 people put on treatment for MDR-TB – cumulative for 2013-2018
Source: UNDP
Grant details
